Tempus is boosting its cancer offerings with a deal to buy out Personalis three years after the pair first teamed up in oncology.
Source: FierceHealthcare
You may also like
Insurers Hedge on Trump-Backed Pledge To Improve...
Violence Repeatedly Erupts at Dementia Care Facilities...
Doctors ‘Cringe’ at Possibility of Documenting...
Pregnant Woman’s Roadside Death Triggers Push To...
Tempus to buy cancer test-maker Personalis for $1.5B
Resmed ventilator safety issue linked to 5 serious...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.